Financial results for the period ended March 31, 2026
As filed · Neuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
What happened
FactNeuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. Financial Results. Recommended payment of final dividend of Rs. 34/- (340 %) per equity share on a face value of Rs.10 each,.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
WithdrawnWe were told that it's a $5 billion, $6 billion, just the CDMO space, $5 billion, $6 billion market opportunity, and it has a very healthy CAGR as an industry because there's a lot of GLP-1s coming in.
I think we're in a similar kind of a situation with peptides where we believe it will grow.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- I think the 18% to 20% CAGR that we talked about is potential that we see. (management committed by FY27)
Evidence
- Neuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.(opens the original filing in a new tab)
- Earlier statement · Q4 FY26
- Latest statement · Q4 FY26
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +4 corroborating keywords; +5 quantified amount; +3 quantified percentage; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%